Abrupt withdrawal of inhaled corticosteroids does not result in spirometric deterioration in chronic obstructive pulmonary disease: Effect of phenotyping

Annals of Thoracic Medicine

Volumn 7, Issue 4, 2012, Pages 238-242

  Al Kassimi, Feisal A ^a   Alhamad, Esam H ^a   Al Hajjaj, Mohammed S ^a   Abba, Abdullah A ^d   Raddaoui, Emad ^b   Shaikh, Shaffi A ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Pathology Department   (Saudi Arabia)

^c Family and Community Medicine Department   (Saudi Arabia)

^d AHMADU BELLO UNIVERSITY   (Nigeria)

Author keywords

Asthma; COPD; radiology and other imaging; respiratory function tests

Indexed keywords

BUDESONIDE; FORMOTEROL;

ADULT; AGED; ARTICLE; ASTHMA; BASEMENT MEMBRANE; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; PHENOTYPE; SPIROMETRY; TURBINATE;

EID: 84870218885     PISSN: 18171737     EISSN: 19983557     Source Type: Journal    
DOI: 10.4103/1817-1737.102185     Document Type: Article

References (48)

1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. (Pubitemid 46294610)
2. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and futicasone in the treatment of chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2003;361:449-56. (Pubitemid 36173708)
3. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of futicasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303. (Pubitemid 30245717)
4. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone proprionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9. (Pubitemid 46115085)
5. Glaab T, Taube C. Effect of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2011;24:15-22.
6. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and effcacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: A systematic review. Chest 2009;136:1029-38.
7. Barnes PJ. Inhaled corticosteroids in COPD: A controversy. Respiration 2010;80:89-95.
8. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, et al. Effcacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: Results of a 6-month randomized clinical trial. Drugs 2008;68:1975-2000.
9. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T. Effectiveness of futicasone propionate and salmeterol combination delivered via the Diskus devise in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 166:1084-91. (Pubitemid 35178706)
10. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The effcacy and safety of futicasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus Inhaler for the treatment of COPD. Chest 2003;124:834-43. (Pubitemid 37123298)
11. Calverley PM, Kuna P, Monsó E, Costantini M, Petruzzelli S, Sergio F. Beclomethasone/formoterol in the management of COPD: A randomized controlled trial. Respir Med 2010;104:1858-68.
12. Wouters E F M, Postma DS, Fokkenst B, Hop WC, Prins J, Kuipers AF, et al. For the COSMIC group. Withdrawal of futicasone propionate from combined salmeterol/futicasone treatment in patients with COPD causes immediate and sustained disease deterioration: A randomized controlled trial. Thorax 2005;60:480-7. (Pubitemid 40814047)
13. th June 2011.
14. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA. Withdrawal of inhaled corticosteroids in people with COPD in primary care: A randomized controlled trial. Respir Res 2007;8:93.
15. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with Chronic Obstructive Pulmonary Disease. The COPE study. Am J Respir Crit Care Med 2002;166:1358-63. (Pubitemid 35292702)
16. O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airfow obstruction. Am J Respir Crit Care Med 2001;164:365-71. (Pubitemid 32778200)
17. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-34. (Pubitemid 27216654)
18. Bellia V, Battaglia S, Catalano F, Scichilone N, Incalzi RA, Imperiale C, et al. Aging and disability affect misdiagnosis of COPD in elderly asthmatics: The SARA study. Chest 2003;123:1066-72. (Pubitemid 36444362)
19. Al-Kassimi FA, Abba AA, Al-Hajjaj MS, Alhamad EH, Raddaoui E, Shaikh SH. Asthma Masquerading as Chronic Obstructive Pulmonary Disease: A Study of Smokers Fulflling the GOLD defnition of Chronic Obstructive Pulmonary Disease. Respiration 2011;82:19-27.
20. Ten Brinke A. Risk factors associated with irreversible airfow limitation in asthma. Curr Opin Allergy Clin Immunol 2008;8:63-9.
21. Shaya FT, Dongyi D, Okazawa M, Blanchette CM, Wang J, Mapel DW, et al. Burden of concomitant asthma and COPD in Medicaid population. Chest 2008;134:14-9. (Pubitemid 352008758)
22. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-8. (Pubitemid 40380276)
23. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlow AJ, et al. Sputum eosinophila and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomized controlled trial. Lancet 2000;356:1480-5.
24. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9.
25. Fingleton J, Weatherall M, Beasley R. Towards individualized treatment in COPD. Thorax 2011;66:363-4.
26. Shirtcliffe P, Weatherall M, Travers J, Beasley R. The multiple dimensions of airways disease: Targeting treatment to clinical phenotypes. Curr Opin Pulm Med 2011;17:72-8.
27. Fabbri LM, Romagnoli M, Corbetta, Casoni G, Busljetic K, Turato G, et al. Differences in airway infammation in patients with fxed airfow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:418-24. (Pubitemid 36216426)
28. Al-Kassimi FA, Al-Hajjaj MS, Alhamad EH, Abba AA, Raddaoui E, Shaikh SA. Abrupt withdrawal of inhaled corticosteroids in COPD does not produce spirometric deterioration: Role of phenotyping. Ann Thorac Med 2011;6:174.
29. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
30. Fujimoto K, Kitaguchi Y, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classifed using high-resolution computed tomography. Respirology 2006;11:731-40. (Pubitemid 44581437)
31. Soler-Catluña JJ, Cosio B, Izquierdo JL, López-Campos JL, Marin JM, Agüero R, et al. Consensus Document on the mixed asthma-COPD phenotype in COPD. Arch Bronconeumol 2012. [Epub ahead of print].
32. Caramori G, Fabbri M, Paioli D, Falcone F, Severino C, Felisatti G, et al. Asthma is not a common cause of severe chronic respiratory failure in non-smokers: ALOT study. Monaldi Arch Chest Dis 2005;63:84-7. (Pubitemid 41167512)
33. Szafranski W, Polsce JZ. Long-term domiciliary oxygen therapy (LTOT) in Poland in the years 1986-2005 (in Polish). Pneumonol Alergol Pol 2007;75:331-42.
34. Tsuda Y, Nogochi T, Mochizuki H, Makino F, Nanjo Y, Sawabe M. et al. Patients with mild-to-moderate asthma may develop clinically signifcant chronic obstructive pulmonary disease. Respirology 2009;14:529-36.
35. Harmanci E, Kebapci M, Metintas M, Ozkan R. High-resolution computed tomography findings are correlated with disease severity in asthma. Respiration 2002;69:420-6.
36. Bourdin A, Serre I, Flamme A, Vic P, Neveu D, Aubas B, et al. Can endobronchial biopsy analysis be recommended to discriminate between asthma and COPD in routine practice? Thorax 2004;59:488-93. (Pubitemid 38797521)
37. Liesker JJ, Ten Hacken NH, Zeinstra-Smith M, Rutgers SR, Postma DS, Timens W. Reticular basement membrane in asthma and COPD: Similar thickness, yet different composition. Int J Chron Obstruct Pulmon Dis 2009;4:127-35.
38. Mitsunobu F, Mifune T, Ashida K, Hosaki Y, Tsugeno H, Okamoto M, et al. Infuence of age and disease severity on high resolution CT lung densitometry in asthma. Thorax 2001;56:851-6. (Pubitemid 32999832)
39. Boulet LP, Turcotte H, Hudon C, Carrier G, Maltais F. Clinical, physiological and radiological features of asthma with incomplete reversibility compared with those of COPD. Can Respir J 1998;5:270-7.
40. Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma 2005;42:367-72. (Pubitemid 41105707)
41. Barnes PJ. How corticosteroids control infammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148:245-54. (Pubitemid 43804814)
42. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: Inactivation of histone deacetylase. Lancet 2004;363:731-3. (Pubitemid 38296564)
43. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on infammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8. (Pubitemid 27085799)
44. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1635-9.
45. Loppow D, Schleiss MB, Kanniess F, Taube C, Jörres RA, Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway infammation. Respir Med 2001;95:115-21. (Pubitemid 32624442)
46. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: An ultrastructural examination of endobronchial biopsy tissue. Thorax 2002;57:799-803. (Pubitemid 34984979)
47. Saha S, Brightling CE. Eosinophilic airway infammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.
48. El-Kassimi FA. Differentiating asthma and COPD patients (Letter to the editor). Chest 2004;126:653-4; author reply 654-5.